AllDocs -> cancers

Copyright © 1998 by W.B. Saunders Company. All rights reserved. 320 A BASIC INFORMATION DESCRIPTION A malignancy beginning in the plasma cells of the bone marrow. Plasma cells normally produce antibodies to help destroy germs and protect against infection. With myeloma , this function becomes impaired, and the body cannot deal effectively with infection. It can affect the bone marrow of all bones but is most common in the thigh, back, pelvis or upper arms. It is most com- mon in men between ages 50 and 70. A recent report has found a virus associated with multiple myeloma . FREQUENT SIGNS AND SYMPTOMS • Pain in the affected bone. The pain is severe, boring and deep. If the bone collapses, pain spreads to other parts of the body. • Weight loss. • Symptoms of anemia, such as weakness, paleness, tiredness and breathlessness. CAUSES Unknown. ...

Where to Start Sources of Information on Multiple Myeloma Suggestions for resources when you begin to look for information about multiple myeloma . Prepared by the Ninon Bourque Patient Resource Library The Ottawa Hospital Regional Cancer Centre 501 Smyth Road, Ottawa, ON, K1H 8L6 613-737-7700 ext 70107 These resources are provided for information purposes only and are not intended as a substitute for medical care. Inclusion of a resource does not imply endorsement by The Ottawa Hospital. If you have any questions about your healthcare, please consult your healthcare provider. If you would like to have more information about this topic, please contact the Ninon Bourque Patient Resource Library at 613-737-7700 ext. 70107 or consumerhealth@ottawahospital.on.ca . Brochure http://www.cancer.ca Multiple myeloma : what you need to know. 8-page brochure, produced ...

Multiple myeloma A Concise Review of the Disease and Treatment Options Prepared by Brian G. M. Durie, MD Page 2 Contents p 1 Introduction p 2 What is Myeloma ? p 6 History p 11 Epidemiology and Pathophysiology p 14 Clinical Symptoms p 15 Staging and Prognostic Factors p 18 Definition of Clinical Response p 19 Treatment p 36 References Mission Statement Dedicated to improving the quality of life of Myeloma patients while working towards prevention and a cure. This is one of a range of publications covering many aspects of living with Multiple Myeloma . Please contact the IMF (UK) for more details. This is an overview of the history of myeloma , a discussion of pathophysiology, clinical features plus treatment options. It is written for physicians ...

If you are a multiple myeloma patient or caregiver, we would like you to join us as we attempt to help each other. Our meetings are held in London, usually on Wednesday afternoons. Please contact us for times and locations. Watch for meeting notices posted on the bulletin boards at the LRCC or on the LRCC website: www.lrcc.on.ca For more information or to be put in touch with other myeloma patients, please call: Becky Ross (London) (519) 641-7080 bucky03@hotmail.com Jim Barnes (Midwestern Ontario) (519) 887-6163 barnes@scsinternet.com or, to be placed on our mailing list, write: Jim Barnes, 40824 Cardiff Rd., RR#5, Brussels, ON N0G 1H0 Information and support for Multiple Myeloma patients and their caregivers provided through: BI-MONTHLY MEETINGS PEER SUPPORT CONTACT ...

Mayo Clin Proc. • July 2006;81(7):877-879 • www.mayoclinicproceedings.com 877 EDITORIAL Multiple Myeloma : New Options, New Challenges EDITORIAL Address correspondence to Martha Q. Lacy, MD, Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905 (e- mail: lacy.martha@mayo.edu). © 2006 Mayo Foundation for Medical Education and Research See also page 889 T he development of novel agents for the treatment of multiple myeloma (MM) has resulted in a plethora of new combination regimens. The high response rates ob- served with these combination regimens have raised ques- tions about whether autologous stem cell transplantation (ASCT) should still be offered to patients as initial therapy. In this issue of Mayo Clinic Proceedings , Dr Hussein and colleagues 1 report results of their trial combining ...

September, 2003 This Report on Leukemia, Lymphoma and Multiple Myeloma Contains: • Cancers by Age Group and Gender • Incidence Rates by Gender and Race • Survival Probabilities • Risk Factors • Sources of Additional Information The Ohio Cancer Incidence Surveillance System (OCISS) Blood-related cancers originate in the bone marrow (Leukemia and Multiple Myeloma ) or lymphatic tissue (Non-Hodgkin’s and Hodgkin’s Lymphomas). These cancers involve the uncontrolled growth of cells with similar functions and origins and result from an acquired genetic injury to DNA of a single cell, which becomes malignant (cancerous) and multiplies continuously. The accumulation of malignant cells interferes with the body’s production of healthy blood cells and ability to protect itself against infections. ...

SCIENTIFIC AGENDA AND FACULTY 09:00–09:20 Welcome and Overview of Current and Emerging Therapies Kenneth Anderson, MD – Chairperson Chief, Division of Hematologic Neoplasia Director, Jerome Lipper Multiple Myeloma Center Kraft Family Professor of Medicine Harvard Medical School Boston, Massachusetts 09:20–09:35 Use of Glutathione Modulators (Such as Ascorbic Acid) for TRISENOX ® (Arsenic Trioxide) Sensitization in Multiple Myeloma : Preclinical and Clinical Studies Kelvin Lee, MD Associate Professor University of Miami Miami, Florida 09:35–10:15 Single and Combination Therapy Using TRISENOX ® in Patients with Relapsed/ Refractory Multiple Myeloma Mohamad Hussein, MD Director, Myeloma Research Program Cleveland Clinic Foundation Cleveland, Ohio James Berenson, MD ...

Don Baylor Former MLB All-Star, AL MVP and Multiple Myeloma Survivor Former MLB All-Star, AL MVP and multiple myeloma survivor Don Baylor is a new member of the Strike Out Cancer team. As a cancer survivor, family caregiver, and a former player, manager and coach, Baylor knows the benefits of a team approach both on and off the field. He encourages all cancer patients to build their own team of healthcare professionals, support services and loved ones. Born in Austin, Texas, Baylor was drafted in the 2nd round of the 1967 amateur draft by Baltimore. Baylor was known for crowding the plate, and set a new major league career record for being hit by pitches in 1987 (breaking Ron Hunt's modern-day record of 243), finishing his career with 267. That record stood until it was broken in 2005. During his 19-year playing career, Baylor was a power hitter who played for six American League teams: the Baltimore Orioles, ...

Multiple Myeloma Emerging Therapy Rafat Abonour Indiana University School of Medicine Page 2 Multiple Myeloma The First Recognized Case • A 39 year old woman developed severe back pain in 1840. • Two years later she developed severe pain while her husband was carrying her from the fireplace to the bed. • A bitter infusion for her poor appetite was given, but the patient refused it. • Two years later she was admitted to St. Thomas Hospital and was allowed wine, mutton chop, and a pint of porter daily. Page 3 BJH, 2000, 111, 1035-44 Multiple Myeloma The First Recognized case Sarah Newberry, 1844. Fractures of femurs and right humerus Page 4 Multiple Myeloma The First Recognized case • Despite the infusion of orange peel and ...

Page 2 The booklets in this series are intended to provide general information about the diseases they describe. In many cases the treatment of individual patients will differ from that described in the booklets. At all times patients should rely on the advice of their specialist who is the only person with full information about their diagnosis and medical history. © All rights reserved. No part of this publication may be reproduced or transmitted without permission in writing from Leukaemia Research. Leukaemia Research 43 Great Ormond Street, London, WC1N 3JJ 020 7405 0101 www.lrf.org.uk email: info@lrf.org.uk Registered charity 216032 For further advice contact the clinical information team on 020 7269 9060. Series compiled by Ken Campbell, revised 2005. A list of advisors can be found at www.lrf.org.uk/advisors The design of this ...

Corporate Medical Policy Bone Marrow Transplant for Multiple Myeloma File Name: bone_marrow_transplant_for_multiple_myeloma Policy Number: SUR6090.14 Origination: 2/2001 Last Review: 11/2004 Next Review: 11/2006 Description of Procedure or Service This policy addresses high-dose chemotherapy with hematopoietic s tem-cell support as a treatment of mul- tiple myeloma . Bone marrow transplants typically include high-dose chemotherapy (HDC). "High-dose chemotherapy" (HDC) involves the administration of cytotoxic agents for the treatment of can- cer. It uses doses several times greater than the standard therapeutic dose. In some cases, whole body or localized radiotherapy is also given and is included in the term HDC. The rationale for HDC is that many cytotoxic agents act according to a steep dose-response curve . Thus, small increments ...

J Neurosurg 104: 608–610, 2006 608 J. Neurosurg. / Volume 104 / April, 2006 LASMA cell tumors are characterized by monoclonal proliferation of Ig-secreting plasma cells. Multiple myeloma represents the disseminated form of the dis- ease and accounts for more than 10% of hematological ma- lignancies. 12 Neurological complications in MM are most frequently due to spinal cord compression by a bone lesion, paraprotein-related neuropathy, hypercalcemia, hypervis- cosity, or amyloidosis. 3,5 Intracranial locations of MM are rare; usually, these lesions are characterized by diffuse lep- tomeningeal involvement, and they less often appear as a solitary cerebral or dural tumor. 5,8,10 Rarely, myelomatous in- volvement of the dura mater has occurred without affecting the leptomeninges or the cerebral parenchyma. 6,7,13 ...

Living Successfully with Multiple Myeloma By Peter Tischler North Texas Myeloma Support Group by Peter Tischler I’m not the smartest guy around and, to be honest, I’d guess that many people in our group are smarter than me. But I’m very good at one thing: I can absorb an enormous amount of data, condense it into a summary, and communicate the results of that data to other people in such a way that they will understand it. That’s what I did in business and that’s what I’ve been doing with information about myeloma . Mostly, I do this one-on-one when people ask for help. This editorial is an attempt to reach a larger audience of people with our disease. When I was diagnosed with multiple myeloma (MM) and was led to believe that I would only be around for a few years, I thought about what I wanted from medical science. I decided that I wanted quality of life and a chance to ...